Associated Papers
Mutational landscape of lung adenocarcinoma in Czechia.
Ambrozkiewicz F et al.
Cancer Treatment and Research Communications, 2026
Features and efficacy of triple-targeted therapy for patients with EGFR-mutant non-small-cell lung cancer with acquired BRAF alterations who are resistant to epidermal growth factor receptor tyrosine kinase inhibitors.
Li Y et al.
Esmo Open, 2024
Engineering of a high-fidelity Cas12a nuclease variant capable of allele-specific editing.
Wei J et al.
Plos Biology, 2024
Protein Tyrosine Phosphatase Non-Receptor 11 (PTPN11/Shp2) as a Driver Oncogene and a Novel Therapeutic Target in Non-Small Cell Lung Cancer (NSCLC).
Richards CE et al.
International Journal of Molecular Sciences, 2023
Regulation of MEK inhibitor selumetinib sensitivity by AKT phosphorylation in the novel BRAF L525R mutant.
Nakai C et al.
International Journal of Clinical Oncology, 2023
Ongoing progress in BRAF-mutated non-small cell lung cancer.
Abdayem P et al.
Clinical Advances in Hematology & Oncology : H&o, 2022
Genomic Landscape, Clinical Features and Outcomes of Non-Small Cell Lung Cancer Patients Harboring BRAF Alterations of Distinct Functional Classes.
Di Federico A et al.
Cancers, 2022
Targeting BRAF-mutant non-small cell lung cancer: Current status and future directions.
Riudavets M et al.
Lung Cancer (amsterdam, Netherlands), 2022
Lysine acetylation regulates the interaction between proteins and membranes.
Okada AK et al.
Nature Communications, 2021
Prevalence of class I-III BRAF mutations among 114,662 cancer patients in a large genomic database.
Owsley J et al.
Experimental Biology and Medicine (maywood, N.j.), 2021
Identification of pathogenic missense mutations using protein stability predictors.
Gerasimavicius L et al.
Scientific Reports, 2020
Computational algorithms for in silico profiling of activating mutations in cancer.
Jordan EJ et al.
Cellular and Molecular Life Sciences : Cmls, 2019
Targeting oncogenic Raf protein-serine/threonine kinases in human cancers.
Roskoski R
Pharmacological Research, 2018
Classifying BRAF alterations in cancer: new rational therapeutic strategies for actionable mutations.
Dankner M et al.
Oncogene, 2018
Beyond the BRAFV600E hotspot: biology and clinical implications of rare BRAF gene mutations in melanoma patients.
Richtig G et al.
The British Journal of Dermatology, 2017
BRAF mutation as a novel driver of eosinophilic cystitis.
Choi MY et al.
Cancer Biology & Therapy, 2017
Bioinformatics Approach for Prediction of Functional Coding/Noncoding Simple Polymorphisms (SNPs/Indels) in Human BRAF Gene.
Hassan MM et al.
Advances in Bioinformatics, 2016
Reproducible Analysis of Post-Translational Modifications in Proteomes--Application to Human Mutations.
Holehouse AS et al.
Plos One, 2015
Structure-energy-based predictions and network modelling of RASopathy and cancer missense mutations.
Kiel C et al.
Molecular Systems Biology, 2014
Fresh surgical specimens yield breast stem/progenitor cells and reveal their oncogenic abnormalities.
Pommier SJ et al.
Annals of Surgical Oncology, 2012
The structural impact of cancer-associated missense mutations in oncogenes and tumor suppressors.
Stehr H et al.
Molecular Cancer, 2011
The energy landscape analysis of cancer mutations in protein kinases.
Dixit A et al.
Plos One, 2011
Development and applications of a BRAF oligonucleotide microarray.
Kim IJ et al.
The Journal of Molecular Diagnostics : Jmd, 2007
BRAF mutation detection and identification by cycling temperature capillary electrophoresis.
Hinselwood DC et al.
Electrophoresis, 2005